The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

Major drugmakers like Bristol Myers Squibb, Merck & Co, Sanofi, and Roche are preparing for possible tariffs on the ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Merck, Bristol Myers Squibb, Sanofi and Roche had little clarity on the potential impact of President Donald Trump’s ...

Pharma executives emphasise that without urgent action, Europe may face a decline and an acceleration in the departure of ...

Sanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 guidance was reaffirmed.

Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address ...

The board of directors of Sanofi (SNY) have proposed an annual dividend of €3.92 per share, an increase of 4.26% from prior dividend of €3.76 per share.

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read ...

SANOFI CONSUMER HEALTHCARE INDIA LTD - Updates on Open Offer - Rediff MoneyWiz, the personal finance service from Rediff.com equips the user with tools and information in the form of graphs, charts, ...

Roche details plans to handle US tariffs, including moving production and building inventory, while Sanofi runs scenarios but ...

Sanofi reports Q1 growth with Altuviiio sales doubling to €251M and Dupixent reaching €3.5B; company terminates two cancer trials while focusing on immunology leadership ...